A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2018; you can also visit the original URL.
The file type is application/pdf
.
Melatonin exerts anti-oral cancer effect via suppressing LSD1 in patient-derived tumor xenograft models
2017
OncoTarget
Aberrant activation of histone lysine-specific demethylase (LSD1) increases tumorigenicity; hence, LSD1 is considered a therapeutic target for various human cancers. Although melatonin, an endogenously produced molecule, may defend against various cancers, the precise mechanism involved in its anti-oral cancer effect remains unclear. Patient-derived tumor xenograft (PDTX) models are preclinical models that can more accurately reflect human tumor biology compared with cell line xenograft models.
doi:10.18632/oncotarget.16808
pmid:28422711
pmcid:PMC5464909
fatcat:5xr2kucjpfgqnkpwk6chv3yhbm